Sammanfattning
Recent years have seen an increasing interest in the use of low dose naltrexone (LDN) for off-label treatment of pain in
diseases as fibromyalgia, multiple sclerosis and morbus Crohn. The evidence is poor, with only few randomized double-blind
placebo-controlled studies. The studies currently available are reviewed in this paper. LDN could be a potentially useful drug in
the future for the treatment of pain in fibromyalgia, but more studies are needed to verify that it is superior to placebo, and
currently it cannot be recommended as first-line therapy.